SCHEDULE 13G/A: Opaleye Management Discloses 7.6% Passive Stake in iBio, Inc.

Opaleye Management, Inc. has filed an amended Schedule 13G, revealing a 7.6% beneficial ownership stake in iBio, Inc. as of December 31, 2024.

Summary

• Opaleye Management, Inc. and Opaleye, L.P. collectively beneficially own 750,000 shares of iBio, Inc. common stock.
• This ownership represents 7.60% of iBio, Inc.'s common stock outstanding.
• The calculation is based on 9,874,676 shares of common stock issued and outstanding as of February 7, 2025, as reported by iBio, Inc. in its Form 10-Q filed on February 10, 2024.
• The beneficially owned shares include 375,000 shares issuable upon the exercise of warrants that are exercisable within 60 days.
• Opaleye Management, Inc. holds shared voting power and shared dispositive power over all 750,000 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of iBio, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by an institutional investor is generally viewed positively as it indicates confidence in the company, without implying immediate disruptive intentions.

Positives

• A significant beneficial ownership stake (7.6%) by an institutional investor like Opaleye Management can signal confidence in the company's long-term prospects.
• The passive nature of the investment, as certified by Opaleye, suggests stability and no immediate intent to challenge current management or corporate control.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from iBio, Inc. or the reporting entity regarding the company's future operations or financial performance.

Industry Context

This filing reflects an institutional investor's passive stake in a biotechnology company, a common occurrence in the sector where long-term investments are made in companies with promising pipelines or platforms. It does not provide broader industry trends but highlights investor interest in specific companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake can influence investor sentiment and potentially the stock price, signaling a vote of confidence.
• Company Management: The passive nature of the investment, as certified, indicates that Opaleye Management is not seeking to influence or change control of iBio, Inc., providing stability for current management.

Key Dates

Keywords

iBio Inc., Opaleye Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Biotechnology, Pharmaceuticals